5 Lessons Italy’s Sunshine Act Can Borrow From a Decade of Global Transparency Reporting
Table of content
- Lesson 1: Delay Is Its Own Compliance Risk
- Lesson 2: Threshold Design Shapes the Quality, and Usability, of the Data
- Lesson 3: Disclosure Alone Only Moves Behavior So Far
- Lesson 4: Enforcement Credibility Matters as Much as the Statute
- Lesson 5: Italy’s Underrated Advantage: the Codice Fiscale
- Bringing It Together: EFPIA as a Harmonization North Star
Author
Sabrina Morgan is the Head of Global Compliance & Customer Delivery at Vector Health. She oversees global transparency reporting and international disclosure requirements along with the Italian Sunshine Act strategy. She also leads the global client delivery team dedicated to data integrity, compliance solutions, and regulatory alignment for pharmaceutical and MedTech organizations.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance
Italy is not writing on a blank page. It is the latest country to join a movement more than a decade old, which means many implementation mistakes have already been made, documented, and litigated somewhere else.
Lesson 1: Delay Is Its Own Compliance Risk
Italian Sunshine Act was introduced in June 2022, yet as of recent legal commentary, the Sanità Trasparente register still is not operational, the Ministry of Health’s implementing decree, originally due within six months of the law’s entry into force, has moved through years of draft consultations without a final publication in the Gazzetta Ufficiale. France, by comparison, moved from the Loi Bertrand’s enactment in December 2011 to an implementing decree in May 2013. The lesson is not simply about speed but about the compounding risk of a long consultation period.
Once the reporting framework becomes operational, companies that have delayed preparation may have little time to reconstruct historical data and meet the applicable reporting deadlines.
Lesson 2: Threshold Design Shapes the Quality, and Usability, of the Data
France’s €10 disclosure threshold for reportable advantages captures an extraordinarily granular dataset, including relatively low-value meals and other benefits, making Transparence Santé a rich resource for competitive and compliance analytics but also a heavier reporting burden.
Italy’s thresholds—more than €100 per individual transfer or more than €1,000 annually for HCPs, and more than €1,000 per individual transfer or more than €2,500 annually for HCOs—filter out some lower-value transactions and concentrate attention on higher-value, higher-risk interactions. Neither approach is inherently correct, but Italy should be deliberate about the trade-off it has chosen: a cleaner, more analyzable dataset with fewer low-value disclosures, potentially making aggregate patterns easier to analyse, in exchange for less visibility into lower-value interactions that, per the U.S. experience, are often exactly where behavior change first shows up.
Lesson 3: Disclosure Alone Only Moves Behavior So Far
U.S. research provides a more nuanced picture: studies have found significant reductions in meal-related payments following the Physician Payments Sunshine Act, while the primary analyses found no significant reduction in total travel payments. Disclosure changes what companies are willing to be seen doing, but it doesn’t necessarily restrict what they’re allowed to do. France answered this by pairing Loi Bertrand’s disclosure regime with a genuine anti-gift law; most gifts and advantages are prohibited outright unless they meet narrow, documented exceptions, with criminal penalties attached. Italy’s Sunshine Act is, by design, a disclosure statute rather than a restriction statute. As the register comes online, Italian compliance teams and policymakers alike should watch whether disclosure by itself produces the same partial, category-specific behavior shifts seen in the U.S., and whether that’s an acceptable outcome or a gap worth closing.
Lesson 4: Enforcement Credibility Matters as Much as the Statute
Italy’s penalty structure is not toothless on paper: administrative penalties range from €1,000 plus twenty times the disbursement amount for unreported agreements, up to €50,000 for unreported equity or IP income, and as high as €100,000 for false information, with public naming of sanctioned companies on the Ministry’s website. But a penalty schedule only deters behavior if it is actually used.
The U.S. experience shows what credible enforcement can look like in practice: the Department of Justice and other federal authorities have pursued cases involving inaccurate or incomplete Open Payments reporting alongside broader healthcare-fraud allegations. The impact of Italy’s Sunshine Act on HCP engagement will ultimately depend on whether regulators demonstrate a similar willingness to act on what the register reveals, rather than simply publish it.
Lesson 5: Italy’s Underrated Advantage: the Codice Fiscale
Many transparency regimes struggle with a deceptively hard technical problem: reliably matching the same healthcare professional across multiple companies’ submissions when names, titles, and affiliations are recorded inconsistently. This is where fuzzy matching and confidence scoring become essential, and expensive, components of any HCP master database. Italy has a potentially useful identification advantage here: the codice fiscale is a unique tax identifier already embedded in Italian administrative life
Used consistently, the codice fiscale could make recipient identification and matching more reliable across reporting datasets and, in principle, support more consistent identification of the same healthcare professional across submissions. Medical device companies should also consider how Italy’s statutory framework applies to their particular business models, rather than assuming that pharma-sector interpretations automatically translate to MedTech activities.
Bringing It Together: EFPIA as a Harmonization North Star
The European Federation of Pharmaceutical Industries and Associations’ Disclosure Code provides an established European industry framework that predates Italy’s statutory transparency regime. As Sanità Trasparente moves toward activation, Italy has an opportunity to design its technical infrastructure, data formats, matching logic, public search functionality, in a way that’s interoperable with EFPIA-aligned systems elsewhere in Europe, rather than building another isolated national silo. Given Italy’s scale in European pharmaceutical manufacturing, getting this right isn’t just a compliance nicety, it’s a chance to set, rather than follow, the next European standard.
Table of content
- Lesson 1: Delay Is Its Own Compliance Risk
- Lesson 2: Threshold Design Shapes the Quality, and Usability, of the Data
- Lesson 3: Disclosure Alone Only Moves Behavior So Far
- Lesson 4: Enforcement Credibility Matters as Much as the Statute
- Lesson 5: Italy’s Underrated Advantage: the Codice Fiscale
- Bringing It Together: EFPIA as a Harmonization North Star
Italy is not writing on a blank page. It is the latest country to join a movement more than a decade old, which means many implementation mistakes have already been made, documented, and litigated somewhere else.
Lesson 1: Delay Is Its Own Compliance Risk
Italian Sunshine Act was introduced in June 2022, yet as of recent legal commentary, the Sanità Trasparente register still is not operational, the Ministry of Health’s implementing decree, originally due within six months of the law’s entry into force, has moved through years of draft consultations without a final publication in the Gazzetta Ufficiale. France, by comparison, moved from the Loi Bertrand’s enactment in December 2011 to an implementing decree in May 2013. The lesson is not simply about speed but about the compounding risk of a long consultation period.
Once the reporting framework becomes operational, companies that have delayed preparation may have little time to reconstruct historical data and meet the applicable reporting deadlines.
Lesson 2: Threshold Design Shapes the Quality, and Usability, of the Data
France’s €10 disclosure threshold for reportable advantages captures an extraordinarily granular dataset, including relatively low-value meals and other benefits, making Transparence Santé a rich resource for competitive and compliance analytics but also a heavier reporting burden.
Italy’s thresholds—more than €100 per individual transfer or more than €1,000 annually for HCPs, and more than €1,000 per individual transfer or more than €2,500 annually for HCOs—filter out some lower-value transactions and concentrate attention on higher-value, higher-risk interactions. Neither approach is inherently correct, but Italy should be deliberate about the trade-off it has chosen: a cleaner, more analyzable dataset with fewer low-value disclosures, potentially making aggregate patterns easier to analyse, in exchange for less visibility into lower-value interactions that, per the U.S. experience, are often exactly where behavior change first shows up.
Lesson 3: Disclosure Alone Only Moves Behavior So Far
U.S. research provides a more nuanced picture: studies have found significant reductions in meal-related payments following the Physician Payments Sunshine Act, while the primary analyses found no significant reduction in total travel payments. Disclosure changes what companies are willing to be seen doing, but it doesn’t necessarily restrict what they’re allowed to do. France answered this by pairing Loi Bertrand’s disclosure regime with a genuine anti-gift law; most gifts and advantages are prohibited outright unless they meet narrow, documented exceptions, with criminal penalties attached. Italy’s Sunshine Act is, by design, a disclosure statute rather than a restriction statute. As the register comes online, Italian compliance teams and policymakers alike should watch whether disclosure by itself produces the same partial, category-specific behavior shifts seen in the U.S., and whether that’s an acceptable outcome or a gap worth closing.
Lesson 4: Enforcement Credibility Matters as Much as the Statute
Italy’s penalty structure is not toothless on paper: administrative penalties range from €1,000 plus twenty times the disbursement amount for unreported agreements, up to €50,000 for unreported equity or IP income, and as high as €100,000 for false information, with public naming of sanctioned companies on the Ministry’s website. But a penalty schedule only deters behavior if it is actually used.
The U.S. experience shows what credible enforcement can look like in practice: the Department of Justice and other federal authorities have pursued cases involving inaccurate or incomplete Open Payments reporting alongside broader healthcare-fraud allegations. The impact of Italy’s Sunshine Act on HCP engagement will ultimately depend on whether regulators demonstrate a similar willingness to act on what the register reveals, rather than simply publish it.
Lesson 5: Italy’s Underrated Advantage: the Codice Fiscale
Many transparency regimes struggle with a deceptively hard technical problem: reliably matching the same healthcare professional across multiple companies’ submissions when names, titles, and affiliations are recorded inconsistently. This is where fuzzy matching and confidence scoring become essential, and expensive, components of any HCP master database. Italy has a potentially useful identification advantage here: the codice fiscale is a unique tax identifier already embedded in Italian administrative life
Used consistently, the codice fiscale could make recipient identification and matching more reliable across reporting datasets and, in principle, support more consistent identification of the same healthcare professional across submissions. Medical device companies should also consider how Italy’s statutory framework applies to their particular business models, rather than assuming that pharma-sector interpretations automatically translate to MedTech activities.
Bringing It Together: EFPIA as a Harmonization North Star
The European Federation of Pharmaceutical Industries and Associations’ Disclosure Code provides an established European industry framework that predates Italy’s statutory transparency regime. As Sanità Trasparente moves toward activation, Italy has an opportunity to design its technical infrastructure, data formats, matching logic, public search functionality, in a way that’s interoperable with EFPIA-aligned systems elsewhere in Europe, rather than building another isolated national silo. Given Italy’s scale in European pharmaceutical manufacturing, getting this right isn’t just a compliance nicety, it’s a chance to set, rather than follow, the next European standard.
Author
Sabrina Morgan is the Head of Global Compliance & Customer Delivery at Vector Health. She oversees global transparency reporting and international disclosure requirements along with the Italian Sunshine Act strategy. She also leads the global client delivery team dedicated to data integrity, compliance solutions, and regulatory alignment for pharmaceutical and MedTech organizations.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance